217 related articles for article (PubMed ID: 19199866)
1. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Dussault I; Bellon SF
Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
[TBL] [Abstract][Full Text] [Related]
2. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors.
Raeppel SL; Therrien E; Raeppel F
Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.
Raeppel S; Gaudette F; Mannion M; Claridge S; Saavedra O; Isakovic L; Déziel R; Beaulieu N; Beaulieu C; Dupont I; Nguyen H; Wang J; Macleod AR; Maroun C; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2010 May; 20(9):2745-9. PubMed ID: 20363625
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
9. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
[TBL] [Abstract][Full Text] [Related]
10. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
13. Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.
Steinig AG; Li AH; Wang J; Chen X; Dong H; Ferraro C; Jin M; Kadalbajoo M; Kleinberg A; Stolz KM; Tavares-Greco PA; Wang T; Albertella MR; Peng Y; Crew L; Kahler J; Kan J; Schulz R; Cooke A; Bittner M; Turton RW; Franklin M; Gokhale P; Landfair D; Mantis C; Workman J; Wild R; Pachter J; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Aug; 23(15):4381-7. PubMed ID: 23773865
[TBL] [Abstract][Full Text] [Related]
14. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
15. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
[TBL] [Abstract][Full Text] [Related]
16. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
17. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.
Northrup AB; Katcher MH; Altman MD; Chenard M; Daniels MH; Deshmukh SV; Falcone D; Guerin DJ; Hatch H; Li C; Lu W; Lutterbach B; Allison TJ; Patel SB; Reilly JF; Reutershan M; Rickert KW; Rosenstein C; Soisson SM; Szewczak AA; Walker D; Wilson K; Young JR; Pan BS; Dinsmore CJ
J Med Chem; 2013 Mar; 56(6):2294-310. PubMed ID: 23379595
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.
Raeppel SL; Raeppel F; Therrien E
Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
